| Similar Articles |
|---|
 |
The Motley Fool
July 31, 2007
Nathan Parmelee |
Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business.   |
The Motley Fool
August 11, 2006
Ryan Fuhrmann |
Viacom Revives Free from CBS, the media conglomerate is drawing investors' attention. |
The Motley Fool
October 6, 2005
Rick Aristotle Munarriz |
Viacom Counts Sheep Details of the Viacom split are as boring as the split itself. No, things aren't going so well for the moribund media stocks lately, but at least some of them are trying. |
Home Theater
March 9, 2004 |
Echostar Deletes CBS Satellite broadcaster makes good on threat, drops CBS from 16 cities in ongoing dispute with Viacom. |
The Motley Fool
January 18, 2012 |
What Johnson & Johnson Does With Its Cash Over the last five years, Johnson & Johnson shares returned 14%, which drops to -3% without dividends -- not a bad boost to top off otherwise lowly share performance. |
The Motley Fool
August 24, 2010
Brian Orelli |
One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well. |
The Motley Fool
September 5, 2006
Rick Aristotle Munarriz |
Viacom Is on the Move There's plenty going on at the media giant, and not all of it is welcome. Investors, take note. |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years. |
Entrepreneur
March 2002
Jennifer Pellet |
Out of Stock When your stock price is stalled and you can't hope to improve it, is it time for your company to quietly step back into private life? |
The Motley Fool
May 26, 2010
Brian Orelli |
Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues. |
The Motley Fool
June 28, 2011
Eric Bleeker |
Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales? |
CFO
May 1, 2010
Alix Stuart |
"Massive Ratings Don't Always Translate into Big Profits." Programming a TV network is both art and science, and this CFO is happy to supply the science. An interview with Michael Pickrum, CFO of Black Entertainment Television LLC. |
Salon.com
April 5, 2001
Dalton Conley |
How to widen the black-white wealth gap Ignore the claims of rich, black estate-tax foes. The tax is good for African-Americans... |
InternetNews
March 16, 2007
Nicholas Carlson |
March Madness Strikes YouTube Two years divorced from Viacom, CBS suits up on YouTube's side of the court. The basketball court that is. |
The Motley Fool
January 23, 2008
Brian Orelli |
A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar. |
The Motley Fool
November 2, 2005
Steven Mallas |
Viacom's Next Stop: Splitsville The company reports much-improved earnings ahead of its split into one growth business and one cash-cow business. Other big media corporations and investors alike should be watching this one. |
The Motley Fool
March 28, 2007
Steven Mallas |
Viacom Revisited: Buying Its Way to Success Viacom had an interesting year as a stand-alone entity. The big risk going forward is that management suddenly loses its ability to keep on top of cultural trends -- its brands must never lose their edgy appeal. Investors, take note. |
The Motley Fool
August 27, 2010
Brian Orelli |
A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much. |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
August 14, 2007
Brian Orelli |
A No-Win Situation Johnson & Johnson is suing the beloved American Red Cross for trademark infringement. Johnson & Johnson just needs to walk a fine line between having its brand eroded by the Red Cross and having its brand eroded by a public relations nightmare. |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
The Motley Fool
December 11, 2006
Rick Aristotle Munarriz |
Fool on the Street: Viacom Plants the Flag Viacom's new CEO shoots for the stars. Let's hope that shareholders enjoy the ride. |
The Motley Fool
July 12, 2011
Todd Wenning |
What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors. |
The Motley Fool
September 15, 2009
Brian Orelli |
What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri. |
HBS Working Knowledge
May 15, 2006
Diane Coutu |
LBJ's Deliberate March for Power When a leader gets enough power -- when he's president of the United States or CEO of a major corporation -- then we can see what he wanted to accomplish all along. Here, a Harvard expert discusses Lyndon B. Johnson's strategy for getting close to powerful people. |
Sports Central
July 30, 2010
Jeffrey Boswell |
Sports Q&A: Jimmy Johnson's Market Penetration What should we make of Johnson's status as a celebrity endorser and reality star? |
Wired
March 2001
Chip Bayers |
Crash Course At 23, Matt Johnson had it all: the business plan, the VC money, and grand designs to dominate the untapped college market. Then the BigWords boy wonder got a harsh lesson in dotcom reality... |
The Motley Fool
May 28, 2010
Brian Orelli |
How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem? |
The Motley Fool
August 8, 2005
Steven Mallas |
Viacom: All About the Split Viacom had a highly rated second quarter, but it's the planned split that counts now. Investors, read on. |
The Motley Fool
November 9, 2006
Shruti Basavaraj |
The Best Blue Chip for 2007: Johnson & Johnson If you're out looking for the best blue chip money can buy, consider Johnson & Johnson. The stock combines strong growth opportunities with stability. It's the ideal stock to build the core of your portfolio. |
The Motley Fool
March 9, 2004
Alyce Lomax |
EchoStar, Viacom Go for the Jugular Disputes over rate hikes have the two companies in a very public battle. |
The Motley Fool
October 17, 2006
Brian Lawler |
See Johnson & Johnson Crawl Earnings growth isn't moving right along because the company has become so big. Investors, take note. |
The Motley Fool
September 14, 2009
Brian Orelli |
The Clock Is Ticking for Elan Elan is getting closer to the Sept. 26 deadline to fix its contract with Johnson & Johnson. If it doesn't, Biogen Idec has the right to take full control of Elan's and Biogen's multiple-sclerosis drug, Tysabri. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
Fast Company
June 2012
Christina Chaey |
Three Things Magic Johnson's New Cable Network Can Learn From Oprah's OWN Flops Magic Johnson is launching Aspire, a cable network of uplifting programming. An industry expert explains why Johnson's network might just have a shot. |
The Motley Fool
October 12, 2004
Alyce Lomax |
Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson? |
The Motley Fool
November 17, 2006
Brian Lawler |
Johnson & Johnson's Good Deal If Conor's stent design can alleviate some of the perceived safety worries about stents, then sales from the Cordis division should spring back up, again making it drive revenue growth for Johnson & Johnson, as it did before this year. Investors, take note. |
The Motley Fool
December 4, 2008
Rick Aristotle Munarriz |
Throw This Stock Away Viacom may be a force in free on-demand video streaming, but once the playing field has been completely leveled, there will be too much content chasing too few eyeballs. |
The Motley Fool
April 29, 2011
David Williamson |
Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes. |
The Motley Fool
December 29, 2011
Matt Thalman |
3 Companies That Give Back to Shareholders These three companies have consistently increased the value of each outstanding share: UPS... Johnson & Johnson... ExxonMobil... |
The Motley Fool
May 20, 2009
Brian Orelli |
Johnson & Johnson Tries to Pull a Travolta Johnson & Johnson seems to be making a comeback, after its drug-eluting stent market share fell precipitously to just 15% in the first quarter. |
BusinessWeek
February 23, 2004
Lowry et al. |
Mega Media Mergers: How Dangerous? If Comcast wins Disney, a few behemoths will dominate news, entertainment, and distribution |
InternetNews
December 19, 2007
Stuart J. Johnston |
Microsoft, Viacom in $500 Million Ad Deal Microsoft and cable giant Viacom announced Wednesday they've inked a deal to help Microsoft expand its online advertising presence. |
The Motley Fool
September 26, 2006
Steven Mallas |
Fool on the Street: Viacom's New Vector New Viacom CEO Philippe Dauman reveals his plans for growth. If he can leverage the main strengths of the company's cable-network division and brand portfolio, he should be able to create synergies between its departments. Investors, take note. |
The Motley Fool
July 19, 2011
Brian Orelli |
J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile. |
The Motley Fool
October 13, 2008
Brian Orelli |
Foolish Forecast: J&J's Diversity Counts Views you can use to get clues on tomorrow's news |
The Motley Fool
October 19, 2010
Brian Orelli |
Watch a 40% Decline Disappear The greatest thing going for Johnson & Johnson is its diversity in product offerings. |
The Motley Fool
May 22, 2009
Brian Orelli |
J&J and Cougar: Meow or Roar? Health-care giant Johnson & Johnson is doing something that many of its investors -- Buffett included -- wouldn't do; it's buying a development-stage drugmaker that has no proven drugs. |
The Motley Fool
December 1, 2010
Brian Orelli |
We're Still Buying. Probably. Despite manufacturing problems, Johnson &Johnson continues with its purchase of Crucell. |
